JP7391226B2 - ピリミジン化合物の結晶 - Google Patents

ピリミジン化合物の結晶 Download PDF

Info

Publication number
JP7391226B2
JP7391226B2 JP2022536418A JP2022536418A JP7391226B2 JP 7391226 B2 JP7391226 B2 JP 7391226B2 JP 2022536418 A JP2022536418 A JP 2022536418A JP 2022536418 A JP2022536418 A JP 2022536418A JP 7391226 B2 JP7391226 B2 JP 7391226B2
Authority
JP
Japan
Prior art keywords
crystal
compound
crystals
type
fumaric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022536418A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022014638A1 (cg-RX-API-DMAC7.html
Inventor
浩之 中村
博義 山中
隆宏 浅井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of JPWO2022014638A1 publication Critical patent/JPWO2022014638A1/ja
Application granted granted Critical
Publication of JP7391226B2 publication Critical patent/JP7391226B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Liquid Crystal Substances (AREA)
JP2022536418A 2020-07-15 2021-07-14 ピリミジン化合物の結晶 Active JP7391226B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020121520 2020-07-15
JP2020121520 2020-07-15
PCT/JP2021/026460 WO2022014638A1 (ja) 2020-07-15 2021-07-14 ピリミジン化合物の結晶

Publications (2)

Publication Number Publication Date
JPWO2022014638A1 JPWO2022014638A1 (cg-RX-API-DMAC7.html) 2022-01-20
JP7391226B2 true JP7391226B2 (ja) 2023-12-04

Family

ID=79554693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022536418A Active JP7391226B2 (ja) 2020-07-15 2021-07-14 ピリミジン化合物の結晶

Country Status (12)

Country Link
US (1) US12492208B2 (cg-RX-API-DMAC7.html)
EP (1) EP4183788A4 (cg-RX-API-DMAC7.html)
JP (1) JP7391226B2 (cg-RX-API-DMAC7.html)
KR (1) KR102914926B1 (cg-RX-API-DMAC7.html)
CN (1) CN116249534B (cg-RX-API-DMAC7.html)
AU (1) AU2021307245B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023000765A2 (cg-RX-API-DMAC7.html)
MX (1) MX2023000692A (cg-RX-API-DMAC7.html)
MY (1) MY207540A (cg-RX-API-DMAC7.html)
PH (1) PH12023550116A1 (cg-RX-API-DMAC7.html)
TW (1) TWI905228B (cg-RX-API-DMAC7.html)
WO (1) WO2022014638A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022282261A1 (en) * 2021-05-24 2023-12-21 Taiho Pharmaceutical Co., Ltd. Treatment methods for subjects with cancer having an aberration in egfr and/or her2

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013118817A1 (ja) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
WO2017038838A1 (ja) 2015-09-01 2017-03-09 大鵬薬品工業株式会社 新規なピラゾロ[3,4-d]ピリミジン化合物又はその塩
WO2020145374A1 (ja) 2019-01-11 2020-07-16 大鵬薬品工業株式会社 ピリミジン化合物又はその塩
WO2022014639A1 (ja) 2020-07-15 2022-01-20 大鵬薬品工業株式会社 Egfr阻害剤
WO2022014640A1 (ja) 2020-07-15 2022-01-20 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
TWI605049B (zh) * 2015-01-30 2017-11-11 Taiho Pharmaceutical Co Ltd Novel salts of condensed pyrimidine compounds and their crystallization
SG11201708793SA (en) * 2015-05-12 2017-11-29 Taiho Pharmaceutical Co Ltd Crystals of azabicyclic compound
JP7223684B2 (ja) * 2017-02-28 2023-02-16 大鵬薬品工業株式会社 ピラゾロ[3,4-d]ピリミジン化合物を用いた抗腫瘍効果増強剤
WO2020004546A1 (ja) 2018-06-28 2020-01-02 日本電気株式会社 遠隔制御装置、遠隔制御方法及びプログラム
TWI769395B (zh) 2018-08-29 2022-07-01 日商大鵬藥品工業股份有限公司 以吡唑并[3,4-d]嘧啶化合物為有效成分之治療劑
JP7164455B2 (ja) 2019-01-31 2022-11-01 理想科学工業株式会社 容器

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013118817A1 (ja) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
WO2017038838A1 (ja) 2015-09-01 2017-03-09 大鵬薬品工業株式会社 新規なピラゾロ[3,4-d]ピリミジン化合物又はその塩
WO2020145374A1 (ja) 2019-01-11 2020-07-16 大鵬薬品工業株式会社 ピリミジン化合物又はその塩
WO2022014639A1 (ja) 2020-07-15 2022-01-20 大鵬薬品工業株式会社 Egfr阻害剤
WO2022014640A1 (ja) 2020-07-15 2022-01-20 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ

Also Published As

Publication number Publication date
PH12023550116A1 (en) 2024-06-24
KR20230034341A (ko) 2023-03-09
CA3189457A1 (en) 2022-01-20
MX2023000692A (es) 2023-02-13
TWI905228B (zh) 2025-11-21
AU2021307245A1 (en) 2023-03-02
US20230331730A1 (en) 2023-10-19
MY207540A (en) 2025-03-04
AU2021307245B2 (en) 2024-02-29
TW202216717A (zh) 2022-05-01
EP4183788A4 (en) 2024-07-17
US12492208B2 (en) 2025-12-09
WO2022014638A1 (ja) 2022-01-20
CN116249534B (zh) 2025-03-25
CN116249534A (zh) 2023-06-09
EP4183788A1 (en) 2023-05-24
KR102914926B1 (ko) 2026-01-19
JPWO2022014638A1 (cg-RX-API-DMAC7.html) 2022-01-20
BR112023000765A2 (pt) 2023-02-07

Similar Documents

Publication Publication Date Title
KR102873219B1 (ko) Egfr 저해제
KR102640463B1 (ko) 피리미딘 화합물 또는 그 염
WO2013007184A1 (zh) 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
US10899744B2 (en) Crystalline form of compound suppressing protein kinase activity, and application thereof
US10280174B2 (en) Salt of fused pyrimidine compound and crystal thereof
CN116249534B (zh) 嘧啶化合物的结晶
US20250276973A1 (en) Crystal of 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
CA3189457C (en) Crystal of pyrimidine compound
RU2828232C1 (ru) Кристалл соединения пиримидина
HK40087564A (en) Crystal of pyrimidine compound
HK40087564B (en) Crystal of pyrimidine compound
JP7282787B2 (ja) ピラゾロ[3,4-d]ピリミジンの結晶
WO2016050016A1 (zh) 作为激酶抑制剂的取代杂环化合物及其制备方法和用途
EA041596B1 (ru) Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231121

R150 Certificate of patent or registration of utility model

Ref document number: 7391226

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150